Half-year report · Q2
9987.TEDINET S100UQEL
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.20T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥2.39T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥17.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥16.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥38.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥29.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥23.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥15.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.22T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.23T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥790.0bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥812.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥429.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥416.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥427.9bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥125.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥181.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥142.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥198.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥223.9bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥56.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥87.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥86.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥10.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥8.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥31.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥261.16 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥357.88 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥191.98 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥7m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥126m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥26.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥20.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥158.9bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥143.7bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥890m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.16T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥25.6bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.39T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.20T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥189.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥16.9bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.6bn |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥519m |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥127.0bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.2bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥112.8bn |
| jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥510m |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.15T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.13T |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥25.4bn |
| jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.35T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥157.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥16.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 490
| Item | Context | Value | Unit |
|---|---|---|---|
| Capital surplus | CurrentQuarterInstant | 32147000000 | JPY |
| Retained earnings | Prior1YearInstant | 332710000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 349879000000 | JPY |
| Treasury stock | Prior1YearInstant | -486000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -357000000 | JPY |
| Shareholders equity | Prior1YearInstant | 378188000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 395215000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 39905000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 35475000000 | JPY |
| Revaluation reserve for land | Prior1YearInstant | -4769000000 | JPY |
| Revaluation reserve for land | CurrentQuarterInstant | -4769000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 1939000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 2963000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 1043000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 851000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 38118000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 34521000000 | JPY |
| Non controlling interests | Prior1YearInstant | 121000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 125000000 | JPY |
| Net assets | Prior1YearInstant | 416428000000 | JPY |
| Net assets | CurrentQuarterInstant | 429862000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 1228686000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 1219852000000 | JPY |
| Net sales | Prior1YTDDuration | 1194472000000 | JPY |
| Net sales | CurrentYTDDuration | 1197323000000 | JPY |
| Cost of sales | Prior1YTDDuration | 1103650000000 | JPY |
| Cost of sales | CurrentYTDDuration | 1102741000000 | JPY |
| Gross profit | Prior1YTDDuration | 90821000000 | JPY |
| Gross profit | CurrentYTDDuration | 94581000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 74255000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 77479000000 | JPY |
| Operating income | Prior1YTDDuration | 16566000000 | JPY |
| Operating income | CurrentYTDDuration | 17101000000 | JPY |
| Interest income noi | Prior1YTDDuration | 84000000 | JPY |
| Interest income noi | CurrentYTDDuration | 79000000 | JPY |
| Dividends income noi | Prior1YTDDuration | 733000000 | JPY |
| Dividends income noi | CurrentYTDDuration | 711000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YTDDuration | 405000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYTDDuration | － | JPY |
| Real estate rent noi | Prior1YTDDuration | 151000000 | JPY |
| Real estate rent noi | CurrentYTDDuration | 146000000 | JPY |
| Other noi | Prior1YTDDuration | 482000000 | JPY |
| Other noi | CurrentYTDDuration | 324000000 | JPY |
| Non operating income | Prior1YTDDuration | 1858000000 | JPY |
| Non operating income | CurrentYTDDuration | 1262000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 22000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 19000000 | JPY |
| Equity in losses of affiliates noe | Prior1YTDDuration | － | JPY |
| Equity in losses of affiliates noe | CurrentYTDDuration | 1083000000 | JPY |
| Rent expenses on real estates noe | Prior1YTDDuration | 121000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |